Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESRRA | P11474 | 16/20 | 0.66 |
| ▸ | ESRRB | O95718 | 1/20 | 0.66 |
| ▸ | ESR1 | P03372 | 1/20 | 0.66 |
| ▸ | ESRRG | P62508 | 1/20 | 0.66 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | XDH | P47989 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4435405 | 1.00 | ESRRA (0.66) | ESRRAESRRBESR1ESRRGESR2 | |
| SCHEMBL2381961 | 0.92 | ESRRA (0.78) | ESRRAESRRBESR1ESRRGESR2 | |
| SCHEMBL8158706 | 0.92 | ESRRA (0.78) | ESRRAESRRBESR1ESRRGESR2 | |
| SCHEMBL2381958 | 0.92 | ESRRA (0.78) | ESRRAESRRBESR1ESRRGESR2 | |
| SCHEMBL8156842 | 0.84 | ESRRA (0.85) | ESRRAESRRBESR1ESRRGESR2 | |
| SCHEMBL2380997 | 0.84 | ESRRA (0.85) | ESRRAESRRBESR1ESRRGESR2 | |
| SCHEMBL2380995 | 0.84 | ESRRA (0.85) | ESRRAESRRBESR1ESRRGESR2 | |
| SCHEMBL648931 | 0.81 | ESRRA (0.79) | ESRRAESRRBESR1ESRRGESR2 | |
| SCHEMBL8163017 | 0.81 | ESRRA (0.79) | ESRRAESRRBESR1ESRRGESR2 | |
| SCHEMBL648930 | 0.81 | ESRRA (0.79) | ESRRAESRRBESR1ESRRGESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580832-B2 | Substituted phenoxy aminothiazolones as estrogen related receptor-α modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-11-12 | — | — | US | disclosed |
| EP-2134698-A1 | SUBSTITUTED PHENOXY AMINOTHIAZOLONES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS | Janssen Pharmaceutica, N.V. (BE) | 2009-12-23 | — | — | EP | disclosed |
| WO-2008109737-A1 | SUBSTITUTED PHENOXY AMINOTHIAZOLONES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-09-12 | — | — | WO | disclosed |
| US-20080221179-A1 | SUBSTITUTED PHENOXY AMINOTHIAZOLONES as estrogen related receptor-alpha modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221179-A1 | SUBSTITUTED PHENOXY AMINOTHIAZOLONES as estrogen related receptor-alpha modulators | ESR2, ESRRA, ESRRG | ESRRA 2/4885ESRRB 4/4885ESR1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.